Your browser doesn't support javascript.
loading
The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
Vlaar, Alexander P J; Lim, Endry H T; de Bruin, Sanne; Rückinger, Simon; Pilz, Korinna; Brouwer, Matthijs C; Guo, Ren-Feng; Heunks, Leo M A; Busch, Matthias H; van Paassen, Pieter; Riedemann, Niels C; van de Beek, Diederik.
Afiliação
  • Vlaar APJ; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Lim EHT; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • de Bruin S; Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Rückinger S; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Pilz K; Metronomia Clinical Research GmbH, Munich, Germany.
  • Brouwer MC; InflaRx GmbH, Jena, Germany.
  • Guo RF; Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Heunks LMA; InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, USA.
  • Busch MH; Department of Intensive Care, VU Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • van Paassen P; Department of Immunology, Maastricht UMC+, Maastricht, The Netherlands.
  • Riedemann NC; Department of Immunology, Maastricht UMC+, Maastricht, The Netherlands.
  • van de Beek D; InflaRx GmbH, Jena, Germany.
Clin Transl Sci ; 15(4): 854-858, 2022 04.
Article em En | MEDLINE | ID: mdl-35029045
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article